Disagree....... sage had series of clinical failures.......... Imu on the other hand are going good (registrationaltrial phase2 will make it great this year)with Azercell. And rest are work in progress.
So far Imu are on track with their clinical trials (barring a few delays mainly with vaxinia trial updates postponement). No comparison really.
2025 imu's clinical trials will alone decide imu's own fate, period.
Out of 3 how many will enter phase2 will decide SP. Not shorters, not hotcoppers(includes our lovely neighbours) or anyone else. Imu clearly has its future in its own hands.
Dyor
spidey
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $82.13M | |||
| Open | High | Low | Value | Volume |
| 1.1¢ | 1.2¢ | 1.1¢ | $338.0K | 30.69M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 3480808 | 1.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.2¢ | 10994115 | 28 |
View Market Depth
| Last trade - 16.10pm 26/06/2025 (20 minute delay) ? |
| IMU (ASX) Chart |